Nicola Deidre Petal Greenway

CIK: 0002123546

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (80.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TAK

TAKEDA PHARMACEUTICAL CO LTD

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

TAK
TAKEDA PHARMACEUTICAL CO LTD
Aug 18, 2026
Sale(S)
Direct
13K shares at avg. $18.11$235K
TAK
TAKEDA PHARMACEUTICAL CO LTD
Aug 10, 2026
Sale(S)
Direct
6.8K shares at avg. $17.10$116K
TAK
TAKEDA PHARMACEUTICAL CO LTD
Aug 10, 2026
Sale(S)
Direct
975 shares at avg. $17.50$17K
TAK
TAKEDA PHARMACEUTICAL CO LTD
Aug 10, 2026
Sale(S)
Direct
33.6K shares at avg. $17.51$589K
TAK
TAKEDA PHARMACEUTICAL CO LTD
Jul 1, 2026
Award(A)
Direct
22.6K shares-

		Type	Shares	Price		Ownership
Aug 18, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Sale(S)	12,980	$18.11	$235,118	Direct
Aug 10, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Sale(S)	6,774	$17.10	$115,835	Direct
Aug 10, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Sale(S)	975	$17.50	$17,063	Direct
Aug 10, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Sale(S)	33,628	$17.51	$588,715	Direct
Jul 1, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Award(A)	22,570	-	$0	Direct

1-5 of 5 transactions

About Greenway Nicola Deidre Petal

Greenway Nicola Deidre Petal (SEC CIK 0002123546) files insider reports with the SEC as Chief Human Resources Officer of TAKEDA PHARMACEUTICAL CO LTD (TAK).

Signal8 holds 5 ownership filings by Greenway Nicola Deidre Petal (1 Form 3, 4 Form 4), filed between Apr 6, 2026 and Aug 19, 2026. Those filings report 5 transactions, from Jul 1, 2026 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Greenway Nicola Deidre Petal's filings is in CAMBRIDGE, MA.

Recent filings by Greenway Nicola Deidre Petal

Aug 18, 2026: Open-market sale of TAK shares (Form 4, code S).
Aug 10, 2026: Open-market sales of TAK shares (3 lines, Form 4, code S).
Jul 1, 2026: Grant or award of TAK shares (Form 4, code A).

Other insiders filing for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Duprey Lauren Rusckowski, Chief Transformation Officer
Plump Andrew Stewart, President, R&D
Farajallah Awny Samaan Botros, Chief Medical Officer
Ibrahim Ramy Riad Ahmed, President, PDT BU
Pacheco Rhonda Janice, President, U.S. Business Unit
Pignagnoli Agosti Marcello, Head, Strat. & Port. Dev

How to read Form 4 transaction codes